生物科技指数ETF-iShares Nasdaq(IBB)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

IBB 生物科技指数ETF-iShares Nasdaq

休市中 09-11 16:00:00 EDT

202.93

+0.29

+0.14%

盘后203.02

+0.09+0.04%

19:37 EDT

最高205.31	最低202.75	成交量228.63万
今开203.94	昨收202.64	日振幅1.26%
总市值102.78亿	流通市值102.78亿	总股本5,065万
成交额4.65亿	换手率4.51%	流通股本5,065万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"IBB","market":"US","secType":"STK","nameCN":"生物科技指数ETF-iShares Nasdaq","latestPrice":202.93,"timestamp":1789156800000,"preClose":202.64,"halted":0,"volume":2286306,"hourTrading":{"tag":"盘后","latestPrice":203.02,"preClose":202.93,"latestTime":"19:37 EDT","volume":32362,"amount":6567264.34,"timestamp":1789169879648,"change":0.09,"changeRate":0.000444,"amplitude":0.000444},"delay":0,"changeRate":0.0014311093564943766,"floatShares":50650000,"shares":50650000,"eps":6.311863,"marketStatus":"休市中","change":0.29,"latestTime":"09-11 16:00:00 EDT","open":203.94,"high":205.31,"low":202.75,"amount":465174036.47682,"amplitude":0.012633,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":6.311863,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":202.64,"sharesOutstanding":50050000,"nav":202.665811,"aum":10325823070.45,"dividendRate":0.001997,"bidAskSpread":0.000286,"preHourTrading":{"tag":"盘前","latestPrice":204.63,"preClose":202.64,"latestTime":"09:25 EDT","volume":602,"amount":123106.38130000001,"timestamp":1789133112066,"change":1.99,"changeRate":0.00982,"amplitude":0.017917},"postHourTrading":{"tag":"盘后","latestPrice":203.02,"preClose":202.93,"latestTime":"19:37 EDT","volume":32362,"amount":6567264.34,"timestamp":1789169879648,"change":0.09,"changeRate":0.000444,"amplitude":0.000444},"volumeRatio":1.6013834487935477,"impliedVol":0.2368,"impliedVolPercentile":0.5299},"requestUrl":"/m/hq/s/IBB","defaultTab":"news","newsList":[{"id":"2666503466","title":"松江奇迹：一家中国药企的“体系化出海”豪赌 ｜ 未来企业调研行","url":"https://stock-news.laohu8.com/highlight/detail?id=2666503466","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666503466?lang=zh_cn&edition=full","pubTime":"2026-09-12 12:14","pubTimestamp":1789186482,"startTime":"0","endTime":"0","summary":"编者按：9月的一天，《华夏时报》未来企业竞争力调研团队来到位于上海松江的复宏汉霖全球生产基地——中国生物制药版图上，一处正在悄悄改写规则的所在。这家中国生物药企拒绝只卖“青苗”，而是试图用生物类似药的现金流，搭建从临床、报批到商业化的全球闭环。但真正的考验在于：创新药管线能否在专利悬崖窗口期兑现为第二增长曲线。上海松江，文俊路618弄。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609123872706781.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609123872706781.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4585","XPH","LU1992135472.HKD","IBB","LU1992135399.USD","LU2272731865.HKD","BK4135","BCG","LU2322448957.HKD","LU2322448791.USD","LU2473716301.USD","LU2272731782.SGD","IE00B5TLWC47.USD","PPH","BK4588","LU2272731600.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666571008","title":"阿斯利康股价盘后跌超2%，因其三期临床试验结果令人失望。","url":"https://stock-news.laohu8.com/highlight/detail?id=2666571008","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666571008?lang=zh_cn&edition=full","pubTime":"2026-09-12 04:23","pubTimestamp":1789158183,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2322448957.HKD","IBB","MRNY","PSCH","PJP","IYH","BK4588","FTXH","IDNA","LU1992135399.USD","FBT","TMED","IEIH","LU2272731600.USD","RXL","SYNB","WDNA","LU2272731865.HKD","RSPH","IBRN","SBIO","LFSC","LU1992135472.HKD","BK4585","LU2322448791.USD","BIB","BIOY","HELX","AZNH","CANC","LU2473716301.USD","IEHS","XBIX","PPH","MEDI","XPH","IE00B5TLWC47.USD","GNOM","BBP","MRNX","BME","LU2272731782.SGD","PBPH","PBE","BBH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666235705","title":"复星医药(600196.SH)子公司地舒单抗生物类似药HLX14注册申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2666235705","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666235705?lang=zh_cn&edition=full","pubTime":"2026-09-11 17:44","pubTimestamp":1789119840,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药 发布公告，近日，公司控股子公司上海复宏汉霖生物技术股份有限公司及其控股子公司自主研发的地舒单抗生物类似药HLX14120mg/瓶规格的药品注册申请获国家药品监督管理局受理。此次申报适应症为其参照药安加维于中国境内已获批上市的所有适应症。据悉，HLX14为公司自主研发的地舒单抗生物类似药。截至公告日期，HLX14已分别于美国、欧盟、英国、加拿大获批上市。截至2026年8月，公司现阶段针对HLX14的累计研发投入约为3.52亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495051.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK0096","LU2272731600.USD","BK0175","IBB","LU1992135472.HKD","BK4588","BK1191","LU2322448957.HKD","600196","XPH","PPH","02196","LU2272731782.SGD","BK0187","BK0028","LU1992135399.USD","BK0196","IE00B5TLWC47.USD","BK0012","LU2322448791.USD","LU2272731865.HKD","BK0239","LU2473716301.USD","BK0183","BK0188","BK1593","BK4585","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666356195","title":"对话复宏汉霖朱俊：体系出海要拿“长线收益”，2030年创新药收入将反超生物类似药","url":"https://stock-news.laohu8.com/highlight/detail?id=2666356195","media":"新浪科技","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666356195?lang=zh_cn&edition=full","pubTime":"2026-09-09 21:04","pubTimestamp":1788959040,"startTime":"0","endTime":"0","summary":"新浪科技讯 9月9日晚间消息，在2026亚布力论坛夏季年会期间，在与新浪科技的对话中，复宏汉霖执行董事、首席执行官朱俊博士系统阐释了公司“体系出海”战略的底层逻辑。另一种是复宏汉霖坚持的“体系出海”，最终目的是拿到“长线收益”。营收方面，朱俊表示公司上半年实现营收35.88亿元，其中海外收入占比达19%，海外产品销售收入同比大幅提升159.4%至1.05亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-09-09/doc-inirfumn8933987.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2272731600.USD","HK0000165453.HKD","LU1992135472.HKD","LU1992135399.USD","IBBQ","HK0000320264.USD","HK0000306685.HKD","XPH","BK4588","LNGR","159992","LU2473716301.USD","BK1161","BK4585","IBB","LU2272731865.HKD","LU2322448791.USD","LU2272731782.SGD","LU2322448957.HKD","02696","HK0000320223.HKD","MEDX","HK0000306701.USD","PPH","IE00B5TLWC47.USD","BK1574","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666533226","title":"对话复宏汉霖朱俊：体系出海要拿“长线收益”，2030年创新药收入将反超生物类似药","url":"https://stock-news.laohu8.com/highlight/detail?id=2666533226","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666533226?lang=zh_cn&edition=full","pubTime":"2026-09-09 20:54","pubTimestamp":1788958467,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4585","IBBQ","LU1992135399.USD","LU2473716301.USD","BK4588","MEDX","IBB","LU2272731600.USD","LU2322448957.HKD","LNGR","LU1992135472.HKD","IE00B5TLWC47.USD","LU2272731782.SGD","PPH","XPH","LU2322448791.USD","LU2272731865.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666580032","title":"全球118款生物药即将失去专利或独占权，生物类似药的“泼天富贵”来了？","url":"https://stock-news.laohu8.com/highlight/detail?id=2666580032","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666580032?lang=zh_cn&edition=full","pubTime":"2026-09-09 19:42","pubTimestamp":1788954152,"startTime":"0","endTime":"0","summary":"中国市场中生物类似药面临集采降价的潜在压力，而市场的增长潜力在哪？9月8日，在复宏汉霖开放日活动上，波士顿咨询公司（BCG）合伙人杜菁表示，全球正迎来生物类似药发展的重大窗口期，重磅原研药集中进入专利悬崖，叠加欧美政策持续利好，预计2035年全球生物类似药市场规模将突破2400亿美元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609093869495082.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609093869495082.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4585","BK4588","LU2272731600.USD","LU2272731782.SGD","PPH","LU2473716301.USD","LU2322448791.USD","159839","IE00B5TLWC47.USD","LU1992135472.HKD","XPH","IBB","LU1992135399.USD","LU2272731865.HKD","LU2322448957.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666712586","title":"安进（AMGN）联合疗法III期临床达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2666712586","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666712586?lang=zh_cn&edition=full","pubTime":"2026-09-09 16:59","pubTimestamp":1788944360,"startTime":"0","endTime":"0","summary":"金吾财经 | 安进公布，双特异性T细胞衔接器Imdelltra联合阿斯利康PD-L1抑制剂英飞凡，在广泛期小细胞肺癌的后期临床试验中实现总生存期延长。这家加州生物制药企业披露III期DeLLphi-305研究中期数据，该试验达成广泛期小细胞肺癌患者总生存期主要终点。该项全球试验评估该组合作为一线维持治疗，受试者既往接受过包含英飞凡的治疗且病情未发生进展。研究同时达成无进展生存期、客观缓解率两项次要终点。","market":"hk","thumbnail":"https://static.szfiu.com/news/20210810/NjNkZWQ4NGZiN2I3MDYxNDlhOTlmZGM4ZTUwODkzNDUzNTE2.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NjNkZWQ4NGZiN2I3MDYxNDlhOTlmZGM4ZTUwODkzNDUzNTE2.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305840","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBH","AZNH","LU2456880835.USD","LU2242652126.USD","IE0002141913.USD","LU0128525929.USD","BK4599","LU0109394709.USD","PJP","BK4534","BK4566","LU2237443978.SGD","PBE","AMGN","LU1571399168.USD","LU0122379950.USD","LU1829250122.USD","LU2237443382.USD","SG9999001440.SGD","IBB","LU2468319806.SGD","LU0029864427.USD","LU0058720904.USD","IE00BFTCPJ56.SGD","LU2462157665.USD","AZN","BIB","BK4533","BK4585","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","LU0432979614.USD","LU0889565916.HKD","BK4568","LU0708994859.HKD","LU1023059063.AUD","LU2112291526.USD","TBXU","LU2236285917.USD","LU2237443895.HKD","IBBQ","LU2237443622.USD","BK4139","LU0289739699.SGD","LU1267930573.SGD","BK4581","LU2242646821.SGD","IE00B4R5TH58.HKD","LU2089984988.USD","LU0868494617.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666309213","title":"安进-阿斯利康肺癌联合用药在后期临床试验中显著提升生存率","url":"https://stock-news.laohu8.com/highlight/detail?id=2666309213","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666309213?lang=zh_cn&edition=full","pubTime":"2026-09-09 10:39","pubTimestamp":1788921579,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["IBBJ","LU2242652126.USD","IE00B2B36J28.USD","LU0109394709.USD","LU0289739699.SGD","LU2468319806.SGD","LU0868494617.USD","BK4534","BMED","LU2089984988.USD","IE0002141913.USD","IE0009355771.USD","LU2112291526.USD","PJP","IE00BFTCPJ56.SGD","BK4599","LU1061106388.HKD","IE00BJT1NW94.SGD","BBH","LU0320765992.SGD","TBXU","SG9999001440.SGD","LU2242646821.SGD","BK4581","PSYK","LU1983299246.USD","BK4585","IBB","BK4139","IBBQ","BK4533","LU0889565916.HKD","IE00BJJMRZ35.SGD","LU1023059063.AUD","LU1057294990.SGD","LU0058720904.USD","IE00B4R5TH58.HKD","BK4566","LU0122379950.USD","PBE","MDTX","BIB","AMGN","LU1571399168.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112638879","title":"市场风向标：安进股价遭受重创","url":"https://stock-news.laohu8.com/highlight/detail?id=1112638879","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1112638879?lang=zh_cn&edition=full","pubTime":"2026-09-09 05:35","pubTimestamp":1788903338,"startTime":"0","endTime":"0","summary":"“这对安进而言，堪称最糟糕的结局。”——巴克莱分析师艾米丽·菲尔德如此评价。此前，诺华制药公布了其心脏病药物令人失望的试验结果，这一披露不仅让诺华自身承压，更给安进旗下一款重磅药物蒙上了厚厚的阴影。","market":"hk","thumbnail":"https://static.tigerbbs.com/e5b05f9c7e258c0791b0ff14e4bfadad","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/e5b05f9c7e258c0791b0ff14e4bfadad"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2468319806.SGD","LU1057294990.SGD","LU0109394709.USD","LU2112291526.USD","IE00BFTCPJ56.SGD","BIB","LU1983299246.USD","BK4566","LU0058720904.USD","IE00B2B36J28.USD","AMGN","IE00B4R5TH58.HKD","PJP","LU1061106388.HKD","LU0868494617.USD","LU2089984988.USD","LU0320765992.SGD","LU2242646821.SGD","IBB","IE00BJJMRZ35.SGD","IE0009355771.USD","SG9999001440.SGD","LU2242652126.USD","BK4139","BK4585","IE0002141913.USD","BK4599","BK4533","BK4588","TBXU","LU0889565916.HKD","LU1023059063.AUD","BK4581","IE00BJT1NW94.SGD","BK4534","IBBQ","PBE","BBH","LU0122379950.USD","LU0289739699.SGD","LU1571399168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136308873","title":"Assembly Biosciences有望获得高达2.8亿美元里程碑付款及美国境外特许权使用费","url":"https://stock-news.laohu8.com/highlight/detail?id=1136308873","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136308873?lang=zh_cn&edition=full","pubTime":"2026-09-09 04:02","pubTimestamp":1788897732,"startTime":"0","endTime":"0","summary":"Assembly Biosciences公司日前披露，其在海外市场具备资格获取最高达2.8亿美元的里程碑款项，外加相应特许权使用费收入。据悉，这家生物科技企业所预期的资金流入将源自美国以外地区。对Assembly Biosciences而言，这笔潜在收入不仅反映其管线资产的外部合作价值，也可能为其后续研发投入提供坚实支撑。市场人士认为，此类非美国市场的收益结构有助于分散地域风险，增强公司财务韧性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3B42.SGD","LU0965509283.SGD","ASMB","BK4585","LU0889565916.HKD","LU0114720955.EUR","BIB","BK4532","LU1778281490.HKD","LU0823416689.USD","BK4568","IE0002270589.USD","LU2468319806.SGD","IE00BZ1G4Q59.USD","BK4588","LU1037948897.HKD","LU1430594728.SGD","LU1934455194.USD","LU2089984988.USD","LU2357627491.SGD","MEDI","SG9999015978.USD","BK4550","LU0058720904.USD","LU1674673428.USD","LU0965509101.SGD","LU1037948541.HKD","LU0861579265.USD","LU2087621335.USD","LU1023059063.AUD","LU1066051498.USD","BK4566","IE00B19Z3581.USD","LU0859254822.USD","LU1061106388.HKD","LU0882574055.USD","LU1585245621.USD","LU1934455277.USD","SG9999015986.USD","BK4578","LU0109394709.USD","SG9999015945.SGD","BK4583","SG9999015952.SGD","LU2112291526.USD","IE00B3T34201.USD","LU0320765992.SGD","IBB","GILD","LU1839511570.USD","TMED","IE00BSNM7G36.USD","BBH","IE00B7SZLL34.SGD","LU0965508806.USD","LU1066053197.SGD","LU1057294990.SGD","BK4139","LU2324357040.USD","IE00BKVL7J92.USD","LU0289739699.SGD","LU0965509010.AUD","LU1674673691.USD","LU1571399168.USD","LU0234570918.USD","TBXU","LU1934455863.HKD","IBBQ","LU0122379950.USD","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154623157","title":"Assembly Biosciences旗下Gs-1179预计2026年底前将推进至生殖器疱疹二期临床试验阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=1154623157","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154623157?lang=zh_cn&edition=full","pubTime":"2026-09-09 04:02","pubTimestamp":1788897731,"startTime":"0","endTime":"0","summary":"Assembly Biosciences公司日前宣布，其研发管线中的候选药物Gs-1179有望在2026年年底之前顺利迈入针对生殖器疱疹的二期临床试验阶段。生殖器疱疹作为一种常见的性传播感染疾病，全球患者群体庞大，对创新疗法的需求十分迫切。Assembly Biosciences正积极加速该药物的研发进程，以期尽早为患者带来新的治疗选择。业内分析人士指出，若Gs-1179能够顺利通过后续试验的严格考验，将可能重塑该适应症的市场格局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2089984988.USD","LU1037948541.HKD","LU1037948897.HKD","BK4566","TMED","LU0859254822.USD","LU0861579265.USD","BK4583","LU1674673428.USD","IE00B3T34201.USD","LU1839511570.USD","LU0289739699.SGD","BK4585","BMED","LU0823416689.USD","SG9999015945.SGD","GILD","LU0234570918.USD","LU1778281490.HKD","LU2468319806.SGD","SG9999015978.USD","BK4588","IE00B19Z3B42.SGD","IE00BKVL7J92.USD","LU2324357040.USD","IE0002270589.USD","LU1934455277.USD","LU2357627491.SGD","LU0122379950.USD","LU0965508806.USD","LU1934455863.HKD","BK4568","IE00B19Z3581.USD","LU0320765992.SGD","IE00BZ1G4Q59.USD","LU0965509283.SGD","LU2112291526.USD","SG9999015986.USD","IBB","LU1934455194.USD","LU0114720955.EUR","LU0889565916.HKD","BK4578","IBBQ","BK4532","LU1430594728.SGD","TBXU","LU0882574055.USD","LU0965509010.AUD","LU1066051498.USD","LU1571399168.USD","LU1585245621.USD","LU1674673691.USD","IE00B7SZLL34.SGD","LU2087621335.USD","LU0109394709.USD","BK4139","ASMB","IE00BSNM7G36.USD","BIB","LU0058720904.USD","LU1057294990.SGD","LU0965509101.SGD","LU1061106388.HKD","LU1066053197.SGD","MEDI","BK4550","BBH","LU1023059063.AUD","SG9999015952.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115029168","title":"Assembly Biosciences：吉利德独享HSV HPI项目临床开发与商业化权利","url":"https://stock-news.laohu8.com/highlight/detail?id=1115029168","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1115029168?lang=zh_cn&edition=full","pubTime":"2026-09-09 04:01","pubTimestamp":1788897702,"startTime":"0","endTime":"0","summary":"Assembly Biosciences宣布，吉利德科学已保留其HSV HPI项目的独家临床开发及商业化权利。这一决定标志着双方合作进一步深化，吉利德将全权主导该项目的后续推进与市场布局。对于Assembly Biosciences而言，此举不仅明确了合作伙伴的战略优先级，也为其自身聚焦其他管线资源提供了更大灵活性。业内观察人士指出，HSV HPI项目的独家授权，反映了吉利德在抗病毒治疗领域持续加码的雄心，同时也凸显了该类创新疗法在未被满足的医疗需求中所蕴含的巨大潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIB","LU0058720904.USD","LU0234570918.USD","LU0859254822.USD","LU1934455194.USD","SG9999015952.SGD","SG9999015986.USD","LU1057294990.SGD","LU1934455277.USD","LU0109394709.USD","LU0889565916.HKD","IE00B19Z3B42.SGD","LU1066051498.USD","IE00B3T34201.USD","IE00B7SZLL34.SGD","LU0965509101.SGD","ASMB","LU1061106388.HKD","LU2089984988.USD","LU1430594728.SGD","GILD","LU0965509283.SGD","BMED","IE00BSNM7G36.USD","SG9999015945.SGD","MEDI","BK4532","LU1674673691.USD","BK4139","SG9999015978.USD","LU0823416689.USD","BK4585","LU2112291526.USD","LU1585245621.USD","LU1066053197.SGD","TBXU","LU0122379950.USD","LU0114720955.EUR","IE00BZ1G4Q59.USD","BK4566","LU1037948541.HKD","LU1571399168.USD","LU2468319806.SGD","LU1037948897.HKD","LU0320765992.SGD","LU2087621335.USD","LU0965509010.AUD","LU1674673428.USD","BK4550","IE00BKVL7J92.USD","LU0882574055.USD","TMED","IBBQ","BK4588","LU0289739699.SGD","IE00B19Z3581.USD","BK4583","LU0861579265.USD","BK4568","LU1778281490.HKD","LU2357627491.SGD","LU1023059063.AUD","LU2324357040.USD","IE0002270589.USD","LU1839511570.USD","LU1934455863.HKD","LU0965508806.USD","IBB","BK4578","BBH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179230759","title":"Assembly Biosciences行使与吉利德关于HSV解旋酶-引物酶抑制剂项目的美国利润分成选择权","url":"https://stock-news.laohu8.com/highlight/detail?id=1179230759","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1179230759?lang=zh_cn&edition=full","pubTime":"2026-09-09 04:01","pubTimestamp":1788897669,"startTime":"0","endTime":"0","summary":"Assembly Biosciences公司已正式行使与吉利德科学就HSV解旋酶-引物酶抑制剂项目达成的美国利润分成选择权。这一战略举措标志着双方合作进入新阶段，有望加速该抗病毒疗法的临床开发与商业化进程。通过行使该选择权，Assembly Biosciences将能够分享该药物在美国市场的未来收益，同时借助吉利德在抗病毒领域的深厚积累与市场渠道，共同推进这一潜在重磅药物的落地。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739699.SGD","LU0965509283.SGD","LU1674673428.USD","ASMB","BK4583","LU1571399168.USD","TBXU","BBH","LU0965509101.SGD","LU2324357040.USD","BK4568","IE0002270589.USD","SG9999015952.SGD","SG9999015986.USD","LU0889565916.HKD","LU2468319806.SGD","BK4532","IBB","LU1066051498.USD","BK4585","LU0859254822.USD","BK4578","IE00BSNM7G36.USD","IE00BKVL7J92.USD","IE00B7SZLL34.SGD","LU1934455194.USD","LU1934455863.HKD","LU2087621335.USD","LU0882574055.USD","MEDI","BMED","GILD","LU1061106388.HKD","SG9999015945.SGD","LU0234570918.USD","LU0965509010.AUD","LU0965508806.USD","LU2357627491.SGD","LU1839511570.USD","LU1934455277.USD","IE00BZ1G4Q59.USD","LU1037948541.HKD","LU1066053197.SGD","IE00B19Z3B42.SGD","LU2112291526.USD","LU0109394709.USD","LU1037948897.HKD","LU1430594728.SGD","BK4139","IE00B19Z3581.USD","LU0823416689.USD","LU1023059063.AUD","IBBQ","LU1585245621.USD","BK4588","LU0114720955.EUR","LU2089984988.USD","TMED","IE00B3T34201.USD","LU1674673691.USD","LU0861579265.USD","LU1778281490.HKD","LU0320765992.SGD","SG9999015978.USD","BIB","BK4550","BK4566","LU0122379950.USD","LU0058720904.USD","LU1057294990.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111756325","title":"安进股价或创二十余年来最大单日跌幅","url":"https://stock-news.laohu8.com/highlight/detail?id=1111756325","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111756325?lang=zh_cn&edition=full","pubTime":"2026-09-09 02:23","pubTimestamp":1788891793,"startTime":"0","endTime":"0","summary":"安进公司股价近期重挫逾9%，这一跌幅令这家生物技术巨头有望迎来自2000年10月以来最惨淡的单日表现。此番暴跌的导火索，源于诺华制药宣布其心脏病药物pelacarsen在降低心血管事件风险方面未能优于安慰剂，试验宣告失败。周二，礼来股价小幅下挫1.9%。安进的跌势因BMO资本市场的下调评级而进一步加剧，使其沦为标普500指数和纳斯达克100指数中的最大输家。","market":"us","thumbnail":"https://static.tigerbbs.com/95977f976807e41662cc4b3ba02269af","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/95977f976807e41662cc4b3ba02269af"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","LU0122379950.USD","BK4566","BBH","IE00BJJMRZ35.SGD","LU1571399168.USD","BIB","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","LU2242652126.USD","LU2112291526.USD","BK4534","LU2089984988.USD","AMGN","LU0289739699.SGD","BK4588","TBXU","IE0009355771.USD","LU0868494617.USD","LU1983299246.USD","IBBQ","LU1061106388.HKD","LU0320765992.SGD","LU2242646821.SGD","BK4139","LU2468319806.SGD","LU0058720904.USD","LU0889565916.HKD","04332","BK4585","PJP","LU1023059063.AUD","BK4599","IBB","LU1057294990.SGD","PBE","IE0002141913.USD","SG9999001440.SGD","BK4533","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665375527","title":"安进股价下跌7%，创下自2025年6月以来最大单日跌幅。","url":"https://stock-news.laohu8.com/highlight/detail?id=2665375527","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665375527?lang=zh_cn&edition=full","pubTime":"2026-09-08 21:30","pubTimestamp":1788874246,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0289739699.SGD","PJP","BBH","LU0868494617.USD","BK4139","LU1983299246.USD","LU2112291526.USD","BK4534","BK4588","IE00BFTCPJ56.SGD","LU0320765992.SGD","BK4533","LU2242652126.USD","IE00BJJMRZ35.SGD","LU1061106388.HKD","IBB","LU1571399168.USD","LU2242646821.SGD","LU0058720904.USD","SG9999001440.SGD","PBE","LU0889565916.HKD","LU1023059063.AUD","LU2089984988.USD","IBBQ","TBXU","LU0122379950.USD","IE00BJT1NW94.SGD","BIB","IE0002141913.USD","BK4585","AMGN","IE00B2B36J28.USD","IE00B4R5TH58.HKD","BK4566","LU2468319806.SGD","LU1057294990.SGD","LU0109394709.USD","BK4599","BK4581","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115495471","title":"安进Phase 3 Dellphi-305研究重大突破：总生存期获益显著优于度伐利尤单抗单药治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1115495471","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1115495471?lang=zh_cn&edition=full","pubTime":"2026-09-08 21:07","pubTimestamp":1788872830,"startTime":"0","endTime":"0","summary":"安进公司宣布，其Phase 3 Dellphi-305临床研究取得重大成果——与度伐利尤单抗单独用药相比，该疗法在总生存期上展现出显著且具有临床意义的改善。这一里程碑式的发现，无疑为肿瘤治疗领域注入了新的活力与希望。尽管完整的详细数据尚未全面披露，但安进方面表示，其临床意义及安全性特征将在即将召开的重大学术会议上进行详尽报告。安进公司并未止步于此。随着研发管线的持续推进，安进正逐步兑现其以创新疗法攻克严重疾病的承诺。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFTCPJ56.SGD","LU0058720904.USD","LU1023059063.AUD","LU2089984988.USD","BK4599","BBH","LU2112291526.USD","LU2242646821.SGD","LU1061106388.HKD","IE0002141913.USD","BK4566","LU2468319806.SGD","LU0889565916.HKD","BK4585","IE00B2B36J28.USD","BK4533","IE00BJJMRZ35.SGD","TBXU","SG9999001440.SGD","LU1983299246.USD","BK4581","IBBQ","LU0320765992.SGD","IE00B4R5TH58.HKD","BK4139","IBB","LU0289739699.SGD","LU0122379950.USD","BK4534","LU2242652126.USD","LU0109394709.USD","PJP","IE00BJT1NW94.SGD","BK4588","IE0009355771.USD","BIB","LU1057294990.SGD","LU1571399168.USD","LU0868494617.USD","PBE","AMGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109517247","title":"Imdelltra®联合Imfinzi®在一线广泛期小细胞肺癌中展现里程碑式总生存期改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1109517247","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1109517247?lang=zh_cn&edition=full","pubTime":"2026-09-08 21:04","pubTimestamp":1788872687,"startTime":"0","endTime":"0","summary":"Imdelltra®与Imfinzi®的联合疗法，于一线广泛期小细胞肺癌治疗领域，取得了具有划时代意义的总生存期提升。这一突破性进展，不仅为患者带来了新的曙光，也重塑了该领域的治疗格局。从数据层面观察，联合治疗方案的生存获益尤为显著，堪称里程碑式的成就。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","LU0868494617.USD","PJP","BK4581","IE00B2B36J28.USD","BK4534","BK4139","TBXU","IE0002141913.USD","BK4585","IBBQ","BK4588","LU1061106388.HKD","BBH","LU0289739699.SGD","AMGN","IE00BFTCPJ56.SGD","LU1571399168.USD","LU2242652126.USD","LU2242646821.SGD","BK4533","LU0889565916.HKD","LU2089984988.USD","LU1983299246.USD","IE00B4R5TH58.HKD","LU0122379950.USD","LU2112291526.USD","BIB","IE0009355771.USD","LU2468319806.SGD","LU0058720904.USD","LU1057294990.SGD","LU0320765992.SGD","SG9999001440.SGD","IE00BJJMRZ35.SGD","LU1023059063.AUD","IE00BJT1NW94.SGD","PBE","LU0109394709.USD","IBB","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665387373","title":"BMO下调安进及BioNTech评级至“与大市同步”","url":"https://stock-news.laohu8.com/highlight/detail?id=2665387373","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665387373?lang=zh_cn&edition=full","pubTime":"2026-09-08 20:59","pubTimestamp":1788872377,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4566","LU2089984988.USD","LU2242646821.SGD","LU0058720904.USD","BK4139","IE0009355771.USD","LU1057294990.SGD","IBB","LU0122379950.USD","LU0889565916.HKD","AMGN","LU2112291526.USD","IE00BJT1NW94.SGD","PBE","LU0289739699.SGD","LU1983299246.USD","BK4581","BK4599","IE00B4R5TH58.HKD","LU0868494617.USD","IBBQ","LU2242652126.USD","LU1061106388.HKD","BK4588","IE00BJJMRZ35.SGD","BBH","IE0002141913.USD","TBXU","BK4585","LU1571399168.USD","IE00BFTCPJ56.SGD","BK4533","IE00B2B36J28.USD","PJP","LU2468319806.SGD","SG9999001440.SGD","LU0320765992.SGD","BK4534","BIB","LU1023059063.AUD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103332998","title":"美股盘前｜英特尔、甲骨文涨超4%；诺华重挫12%，IONIS下跌10%；阿斯麦新一代EUV光刻机获台积电和三星使用承诺","url":"https://stock-news.laohu8.com/highlight/detail?id=1103332998","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1103332998?lang=zh_cn&edition=full","pubTime":"2026-09-08 20:01","pubTimestamp":1788868860,"startTime":"0","endTime":"0","summary":"9月8日美元指数上升0.0364%，报98.96。03 要闻1. 三大芯片厂全面采购ASML最先进High NA EUV光刻机以扩产高端制程。ASML确认三星、台积电与英特尔已承诺在2028–2030年起量产使用High NA设备，并与ASML签订光罩尺寸升级合作协议，助力降低AI芯片制造成本。","market":"sh","thumbnail":"https://static.tigerbbs.com/ed4ee39e6b0f45214393093d70ba81a8","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/ed4ee39e6b0f45214393093d70ba81a8"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BQXX3F31.USD","LU1066053197.SGD","LU1929549753.HKD","LU1935043536.SGD","LU2211815571.USD","BK4566","SGXZ81514606.USD","LU2357125470.USD","LU0823414478.USD","AIS","IE00B1BXHZ80.USD","LUMA","LU0109392836.USD","LU1720051108.HKD","LU2491049909.HKD","BK4007","LU1815333072.USD","LU2242649171.HKD","OGIG","LU0210536198.USD","BK4138","LU0476273544.USD","LU1804176565.USD","LU0162691827.USD","LU0654597011.USD","BK4147","LU0823417653.USD","LU1201861165.SGD","LU0124676726.USD","LU1074936037.SGD","IE0004091025.USD","BK4602","03165","LU2471134879.HKD","LU2430703251.USD","LU1894683348.USD","LU2106854487.HKD","LU2506951958.HKD","LU0348723411.USD","LU1066051498.USD","DIG","BK4559","AVXC","LU0889566641.SGD","IE00B5TLWC47.USD","LU0683600562.USD","SG9999000418.SGD","IE00BMPRXR70.SGD","SG9999002521.SGD","CGDG","LU2236285917.USD","RSPG","MEMX","LU1839511570.USD","CHPX","IE000M9KFDE8.USD","LU0114720955.EUR","LU1883866441.USD","GNOM","SG9999002224.SGD","LU0444973449.USD","LU2087621335.USD","LU2347655156.SGD","LU1868837722.USD","IE00B66KJ199.SGD","BK4526","EFA","IYE","LU0889565916.HKD","LU2272731865.HKD","BK4023","IEFA","LU1989772840.SGD","LU1992135399.USD","LU2592432038.USD","LU1162221912.USD","LU1323610961.USD","LU1823568750.SGD","LU2087625088.SGD","LU0965509101.SGD","ESIM","LU2543165471.USD","LU0823039010.USD","LU2360106780.USD","LU2360108059.USD","LU2860962120.EUR","LU0321505868.SGD","LU1815336760.USD","CTEX","ILOW","IE0009356076.USD","LU1691799644.USD","LU2896262040.SGD","LU0980610538.SGD","LU0122379950.USD","LU2237443382.USD","LU1057294990.SGD","QTUP","LU0496365809.HKD","LU0545039389.USD","LU2471134796.USD","KNOW","INYY","DXD","LU0823421416.USD","LU2462591277.SGD","LU1037948541.HKD","LU0661504455.SGD","IE00B3S45H60.SGD","LU2237443549.SGD","DIA","FCG","EGGY","BK4529","BK4579","LU1852331112.SGD","LU2092937221.SGD","IBBQ","LU0823421333.USD","LU1582986359.USD","CRAK","LU2271345857.HKD","BK4504","LU0048573561.USD","LU2764263203.CNY","SG9999015358.SGD","CNEQ","ERX","IE0000B7K699.USD","IE0034235303.USD","LU0056508442.USD","IE00B775SV38.USD","IE00BQXX3D17.EUR","LU0211326755.USD","LU1894683264.USD","INT","LU2237957811.SGD","LU0256863811.USD","PXE","BK7104","BK4570","LU2468319806.SGD","LU0097036916.USD","LU0251142724.SGD","LU0225283273.USD","LU0359202008.SGD","LU0368265418.SGD","LU0109394709.USD","FTXN","LU2360107168.USD","LU1917777945.USD","BK4535","LU2505996509.AUD","LU0795875086.SGD","LU2237443622.USD","LU1571399168.USD","LU1935043023.USD","LU0868494617.USD","BK4575","LU0251131958.USD","LU1861215975.USD","LU1430594728.SGD","SG9999015341.SGD","BK4532","VDE","LU1508157978.USD","LU0316494557.USD","BK4082","IE00BJT1NW94.SGD","LU0300736062.USD","SG9999001176.SGD","LU0742534661.SGD","LU0061474960.USD","LU2362541513.USD","LU0353189680.USD","LU0158827948.USD","LU1429558221.USD","HBMX","LU0154245756.USD","LU2746668461.USD","LU0345780950.USD","LU0965509010.AUD","LU2264538146.SGD","LU0203345920.USD","LU1435385759.SGD","LU2458330243.SGD","LU2360032135.SGD","LU0788109394.HKD","IE00BKVL7J92.USD","AIQ","LU1983299246.USD","LU1023057109.AUD","LU0433182093.SGD","LU0528227936.USD","CGIC","LU0084288322.USD","LU0719512351.SGD","LU1582986433.USD","LU2764262908.HKD","BK4599","SGXZ99366536.SGD","FENY","LU0878005551.USD","LU0198837287.USD","LU0431992006.USD","ORCU","EMC","IE00BZ1G4Q59.USD","OZEM","LU0541502299.USD","LU1732799900.SGD","LU0985489474.SGD","LU0211328371.USD","LU2023250504.SGD","LU0158827781.USD","LU0070217475.USD","LU2250418816.HKD","LU2265009873.SGD","LU0878866978.SGD","LU0417517546.SGD","IE00BD6J9T35.USD","LU0942090050.USD","LU1934455863.HKD","TEXU","LU0912757837.SGD","LU2089283258.USD","LU1674673691.USD","LU0149725797.USD","BK4505","GXPE","LU2954938101.SGD","LU0128526141.USD","IE00BHPRN162.USD","LU0266512473.USD","BK4097","SG9999003800.SGD","IE00BBT3K403.USD","LU0070302665.USD","BK4608","LU0058720904.USD","LU1548497426.USD","LU1623119135.USD","LU2746668974.SGD","LU1046421795.USD","TTEQ","LU1778281490.HKD","03145","LU0081259029.USD","HK0000304805.HKD","BK4605","ORCX","LU1093756325.SGD","IE0031619046.USD","LU0612318971.USD","LU2298321311.HKD","LU2322448791.USD","IE0004445239.USD","LU0456854461.SGD","LU0077335932.USD","LU0175139822.USD","WEEI","ORAC","LU0345781412.USD","IE0002141913.USD","LU2237443978.SGD","LU0823416689.USD","UMMA","PXI","LU0143863784.USD","LU1582987324.SGD","LU1868837565.USD","IE00B3CCJ963.GBP","LU2294711713.HKD","BK4612","TINS","LU2129689514.USD","PPH","LU0823417737.USD","IE00B2Q91V27.USD","LU1582987597.SGD","LU0477156953.USD","WUGI","IE00BQXX3C00.GBP","LU2430703095.HKD","LU2089985449.USD","LU2750360997.AUD","LU0130102774.USD","LU0256331488.USD","LU0787776722.HKD","LU0130517989.USD","LU0310799852.SGD","LU2506952097.USD","LU2148611432.USD","IE00BMPRXQ63.HKD","IE00BSNM7G36.USD","LU2505996681.GBP","LU2430703178.SGD","LU2129689431.USD","LU0300736492.USD","LU0234570918.USD","LU1642822529.SGD","LU1989764664.SGD","LU0882574055.USD","BK4585","LU2931357623.SGD","LU0353189763.USD","LU0251132253.USD","SG9999001424.SGD","FENI","BK4538","SG9999001176.USD","LINT","IE000BZT7R73.USD","LU1989771016.USD","DDM","BK4592","LU0052756011.USD","LU0345770308.USD","LU0823434583.USD","LU1734074674.USD","LU2324357040.USD","LU1150488135.SGD","LU2764263039.SGD","BBH","LU0211326839.USD","LU0345774391.USD","LU0157215616.USD","LU0345769128.USD","LU1282649067.USD","LU0029874061.USD","LU0553294199.USD","LU1048588211.SGD","LU0274383776.USD","SG9999004220.SGD","LU2602419157.SGD","SG9999013999.USD","LU2663582299.SGD","BK5113","IE00B7SZL793.SGD","LU0345769631.USD","AVSE","FFGX","BK4141","LU0965509283.SGD","SG9999014542.SGD","LU0138981039.USD","LU0211331839.USD","LU2211814178.USD","BK4548","LU2491050071.SGD","IE00B4R5TH58.HKD","EMM","LU0823434740.USD","IE00BFTCPJ56.SGD","LU1489326972.SGD","LU0795875169.SGD","LU2041044095.USD","TBXU","LU2111349929.HKD","LU0359201885.HKD","XLE","LU2471134523.USD","LU2028103732.USD","IBB","IE00B7SZLL34.SGD","LU2125154778.USD","LU2133065610.SGD","LU0320765992.SGD","LU1235294995.USD","DBEF","LU0859254822.USD","LU0082616367.USD","LU0541501648.USD","LU2054465674.USD","LU0572940350.SGD","FTXL","LU0642271901.SGD","LU0466842654.USD","BK4527","LU0208291251.USD","LU1988902786.USD","LU1064131342.USD","LU0823038988.USD","IE00BZ199S13.USD","LU0965508806.USD","GSID","LU0072461881.USD","LU0444971666.USD","LU1674673428.USD","LU1992135472.HKD","LU2506951875.HKD","UDOW","BK7095","BK4503","BK4543","LU1366333091.USD","BK4578","BK4528","EPAI","IE00BKDWB100.SGD","LU0310800965.SGD","SG9999011175.SGD","SGXZ51526630.SGD","IE000WAW04H5.SGD","LEGR","CHAT","LU0264606111.USD","LU0648000940.SGD","IE00BYQQ9H92.USD","LU0957808578.USD","LU2063271972.USD","LU0320765646.SGD","DOG","LU1712237335.SGD","LU1366192091.USD","LU1585245621.USD","BK4591","LU2089284900.SGD","LU2237957902.USD","BK4581","IFLR","LU1934455194.USD","HK0000304797.USD","LU0266013472.USD","LU1791710582.SGD","LU0154236417.USD","LU0882747503.HKD","CGNG","LU0211327993.USD","IE00B19Z3B42.SGD","IE00BFXG1179.USD","BK4157","LU0878004406.USD","LU1023059063.AUD","IE0009355771.USD","CORO","LU1720051017.SGD","LU0289739699.SGD","LU1934455277.USD","LU0359201612.USD","LU0689626769.HKD","LU0314106906.USD","LU2125154935.USD","LU1153585028.USD","LU1506573853.SGD","LU2750360641.GBP","LU1718418525.SGD","LU2102340556.USD","IE00BKPKM429.USD","LU2290526834.HKD","NVS","GNMX","IEO","LU2247934214.USD","LU0976567544.SGD","IE00BLSP4452.SGD","LU0278409577.USD","LU0266512127.USD","BK4170","LU2112291526.USD","IE00B19Z3581.USD","LU1989764748.USD","ASIA","WQTM","OILT","IGE","LU0289960550.SGD","LU1037948897.HKD","ADVE","LU1316542783.SGD","LU1989772923.USD","IE000F7OJYX1.SGD","LU0630314457.HKD","SPTE","LU0048584097.USD","LU0154245673.USD","IE00BGHQF524.EUR","LU0432979614.USD","IE0002270589.USD","BK4515","LU2473716301.USD","LU0949170772.SGD","IGV","LU1935042991.SGD","DRLL","IE00BJJMRZ35.SGD","LU2089984988.USD","LU2471134952.CNY","THNR","BK4588","IE00B5949003.HKD","LU0128525689.USD","LU2108987350.USD","SG9999001440.SGD","ORCZ","LU1935042488.USD","LU0143863198.USD","LU2242646821.SGD","LU2242652126.USD","PJP","LU0203347892.USD","LU0234572021.USD","LU0823414551.USD","ORCL","LU2272731600.USD","LU2249611893.SGD","BAI","LU0868494708.USD","CGGO","IE00B19Z4B17.USD","LU0950375773.USD","LU0267386448.USD","FDTX","DBEU","BIB","BK4534","IE0004086264.USD","LU2999663052.SGD","LU0170899867.USD","LU1267930490.SGD","LU2244417387.USD","CQTM","LU2326559502.SGD","TNGY","CWI","QQQA","LU1291159041.SGD","IXC","LU1150488218.USD","SDOW","INTC","LU0345770993.USD","LU0098860793.USD","BK4213","LU2129689605.HKD","LU2462611646.USD","LU1035773651.USD","BK4550","LU0321505439.SGD","XNTK","LU2491050154.USD","SG9999014575.USD","CHPS","BK4512","LU0868486357.SGD","IE00BLSP4239.USD","LU1935042215.USD","LU0011850046.USD","LU1211504680.USD","LU0068578508.USD","LU2720916845.USD","LU0187121727.USD","TEK","LU0488056044.USD","IE00BMPRXN33.USD","LU1069347547.HKD","BK4516","LU2487616109.SGD","BK4554","LU0130103400.USD","CNAV","BK4201","LU1201861249.SGD","TRUN","IE00BN8TJ469.HKD","LU1282649810.SGD","TDIV","LU0122376428.USD","LU0323591593.USD","IE00B3M56506.USD","SG9999014559.SGD","IE00B1XK9C88.USD","IE000SO60NU8.SGD","LU2362540622.SGD","BLOX","BK4148","LU0238689110.USD","IE00B2B36J28.USD","LU2498475776.HKD","ORCS","AVEM","SOXX","LU1003077747.HKD","LU2322448957.HKD","FOTO","LU2506952170.USD","BK4533","SPRX","SPWO","MEDX","LU0889565833.HKD","SMH","LU2362541273.HKD","LU0143551892.USD","LU1093756168.USD","LU1861220033.SGD","LU0094547139.USD","LU0792757196.USD","LU2357305700.SGD","LU0210528500.USD","PBE","LU0738911758.USD","LU0345774631.USD","LU1974910355.USD","LU2506951792.HKD","INTW","LU0572939691.SGD","SG9999014567.USD","IE000MB6IJN5.SGD","LU0320765489.SGD","SG9999002232.USD","LU0384037296.USD","BK4139","LU1732800096.USD","LU0648001328.SGD","LU1430597077.USD","LU0053666078.USD","ASMH","IE00BFXG0V08.USD","LU1803068979.SGD","BGIA","PQNT","SPY","LU2272731782.SGD","LU2357627491.SGD","LU0072462343.USD","LU1061106388.HKD","LU1791710400.SGD","IE00BWXC8680.SGD","LU0861579265.USD","LU2023251221.USD","HYDR","LU2458330169.SGD","LU0957791311.USD","LU1267930813.SGD","LU0612318385.USD",".DJI","SGXZ57979304.SGD","DRIV","LU1868838027.USD","LU1267930227.SGD","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665326953","title":"美股异动｜安进盘前跌5.4%，诺华同靶点药物III期临床失败，Lp(a)赛道遭重创","url":"https://stock-news.laohu8.com/highlight/detail?id=2665326953","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665326953?lang=zh_cn&edition=full","pubTime":"2026-09-08 17:07","pubTimestamp":1788858422,"startTime":"0","endTime":"0","summary":"消息面上，诺华于9月4日公布，其与Ionis联合开发的降脂药物Pelacarsen，在名为LpHORIZON的III期临床试验中未能达到主要终点。诺华的Pelacarsen是全球首个针对Lp靶点进行心血管结局验证的III期药物。因此，市场担忧情绪蔓延到了同样在开发Lp药物的安进身上。多家分析机构认为，诺华的失败削弱了但并未完全推翻Lp这一靶点的可行性。安进后续公布的Olpasiran完整试验数据，将成为判断该靶点未来走向的关键。","market":"fut","thumbnail":" http://caiji.3g.cnfol.com/colect/202609/08/20260908512020.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202609/08/20260908512020.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260908/32363493.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["IE00BFTCPJ56.SGD","LU0889565916.HKD","PJP","LU0070302665.USD","BK4599","LU0868494617.USD","LU1061106388.HKD","LU0320765489.SGD","IE0009355771.USD","LU2242652126.USD","LU0109394709.USD","IBBQ","IE00BJJMRZ35.SGD","LU2089984988.USD","BK4588","BIB","BK4585","IBB","PBE","LU2112291526.USD","AMGN","IE0002141913.USD","BK4566","BK4139","IE00B2B36J28.USD","TBXU","LU0289739699.SGD","BK4007","LU1571399168.USD","MEDX","LU2468319806.SGD","LU1983299246.USD","PPH","BK4532","BK4533","LU0320765992.SGD","LU1057294990.SGD","BK4581","SG9999001440.SGD","LU1023059063.AUD","LU0211331839.USD","BK4578","IE00B4R5TH58.HKD","LU0122379950.USD","LU0208291251.USD","BK4534","IE00BJT1NW94.SGD","LU0058720904.USD","NVS","BBH"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0424},{"period":"1month","weight":0.011},{"period":"3month","weight":0.1891},{"period":"6month","weight":0.2261},{"period":"1year","weight":0.4112},{"period":"ytd","weight":0.2024}],"compareEarnings":[{"period":"1week","weight":-0.0077},{"period":"1month","weight":-0.0106},{"period":"3month","weight":0.0304},{"period":"6month","weight":0.154},{"period":"1year","weight":0.1622},{"period":"ytd","weight":0.1208}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"安硕纳斯达克生物科技ETF追踪纳斯达克生物医疗指数(Biotechnology Index)。Biotechnology Index包含的标的为在纳斯达克上市的生物医疗公司。\n风险提示：标的成分和权重，有可能随着时间的迁移而发生变化。","yearOnYearQuotes":[{"month":1,"riseRate":0.722222,"avgChangeRate":0.019108},{"month":2,"riseRate":0.611111,"avgChangeRate":-0.001245},{"month":3,"riseRate":0.555556,"avgChangeRate":0.002788},{"month":4,"riseRate":0.5,"avgChangeRate":0.003638},{"month":5,"riseRate":0.611111,"avgChangeRate":0.009102},{"month":6,"riseRate":0.777778,"avgChangeRate":0.027534},{"month":7,"riseRate":0.722222,"avgChangeRate":0.03565},{"month":8,"riseRate":0.5,"avgChangeRate":0.006092},{"month":9,"riseRate":0.388889,"avgChangeRate":-0.002512},{"month":10,"riseRate":0.388889,"avgChangeRate":-0.014563},{"month":11,"riseRate":0.833333,"avgChangeRate":0.040881},{"month":12,"riseRate":0.555556,"avgChangeRate":0.007272}],"exchange":"NASDAQ","name":"生物科技指数ETF-iShares Nasdaq","nameEN":"iShares Biotechnology ETF"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"生物科技指数ETF-iShares Nasdaq(IBB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供生物科技指数ETF-iShares Nasdaq(IBB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"生物科技指数ETF-iShares Nasdaq,IBB,生物科技指数ETF-iShares Nasdaq股票,生物科技指数ETF-iShares Nasdaq股票老虎,生物科技指数ETF-iShares Nasdaq股票老虎国际,生物科技指数ETF-iShares Nasdaq行情,生物科技指数ETF-iShares Nasdaq股票行情,生物科技指数ETF-iShares Nasdaq股价,生物科技指数ETF-iShares Nasdaq股市,生物科技指数ETF-iShares Nasdaq股票价格,生物科技指数ETF-iShares Nasdaq股票交易,生物科技指数ETF-iShares Nasdaq股票购买,生物科技指数ETF-iShares Nasdaq股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"生物科技指数ETF-iShares Nasdaq(IBB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供生物科技指数ETF-iShares Nasdaq(IBB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}